Area of research
Oncology · Immunology
Research interest
Research interests include CAR-T cell therapy research, Immune Cell Function and Interaction, Acute Myeloid Leukemia Research, and Immunotherapy and Immune Responses.
Mis-splicing-derived neoantigens and cognate TCRs in splicing factor mutant leukemias
CAR-engineered lymphocyte persistence is governed by a FAS ligand–FAS autoregulatory circuit
CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia
International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML
Mis-Splicing Derived Neoantigens and Cognate T Cell Receptors in Splicing Factor Mutant Myeloid Neoplasms
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML
Human cytomegalovirus expands a CD8 <sup>+</sup> T cell population with loss of <i>BCL11B</i> expression and gain of NK cell identity
Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant
Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation
Cytokine IL-36γ improves CAR T-cell functionality and induces endogenous antitumor response
Granulocyte‐colony stimulating factor in <scp>COVID</scp>‐19: Is it stimulating more than just the bone marrow?
CD103+ cDC1 and endogenous CD8+ T cells are necessary for improved CD40L-overexpressing CAR T cell antitumor function
Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System
Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen